AstraZeneca: Calquence granted 'breakthrough therapy' status

(CercleFinance.com) - Alongside its announcement of favourable results for its anticancer drug Lynparza, on Wednesday AstraZeneca also announced that the Food and Drug Administration (FDA) has awarded its leukemia treatment Calquence the status of "breakthrough therapy" which will speed up its marketing.


The FDA's decision concerns the use of Calquence in the treatment of chronic lymphocytic leukaemia, one of the most common types of leukemia, AstraZenica said.

This status has been granted on the basis of two clinical studies that showed that the drug, taken orally, significantly increased the time patients lived without disease progression or death, AstraZeneca said.



Copyright (c) 2019 CercleFinance.com. All rights reserved.